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Conclusions: CT guided high dose brachytherapy can be 
successfully implemented in a cancer centre achieving good 
levels of local control and overall survival. Node positivity on 
original MRI is predictive for recurrence.A complete response 
on week 5 MRI predicts for excellent long term pelvic control. 
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Purpose/Objective: To assess self-reported quality of life 
(QoL) experienced by cervical and endometrial cancer 
patients after radiation therapy and in regular follow up. Our 
purpose is to evaluate QoL related to urinary and bowel 
symptoms and sexual functioning in order to identify patient- 
and disease-related influencing factors. 
Materials and Methods: Since March 2011, 48 patients in 
regular follow-up for cervical cancer staged Ib1-IIIB (26 
operated and 22 non -operated) and to 82 patients in follow 
up for endometrial cancer staged IA-IIIC (76 operated and 6 
non -operated) after postoperative or radical pelvic 
radiotherapy ± brachytherapy boost were invited to fill in the 
anonymous EORTC-QLQ30 questionnaire. This questionnaire 
was combined with EN24 in case of endometrial cancer or CX 
24 in case of cervical cancer. Exclusion criteria was the 
inability to understand the questionnaire. There was no 
limitation with regard to age or performance status. We 
analyzed overall health and overall quality of life, bladder 
symptoms, disuria and bladder and faecal incontinence. We 
also analyzed items related to sexual function (sexual 
interest and activity) and sexual symptoms (vaginal dryness).  
Results: Everybody accepted to compile the questionnaire 
and only 5 patients needed some assistance. Most patients 
found that the questions were clear and easy to understand. 
Median age was 62.3 years (range 29–81). With a median 
follow up of 4.5 years (range 1.2-6.5), 78% of women were 
free of disease and 21% had evidence of tumour progression 
or relapse. All items exhibited good compliance with no 
missing values except those regarding sexual function that 
were missed in 37.5% of patients. The 92.5% of women 
judged their overall health and QoL good. In particular all 
patients with no evidence of tumour relapse judged a 
favorable QoL, and only 36% of patients with progression 
disease judged their QoL poor.  
Table 1 shows the answers considering tumour type and 
treatment modality. 
We calculated the Chi-Square Test to compare treatment 
modalities (operated or non-operated patients; pelvic 
external beam radiotherapy ± brachytherapy) and tumour 
sites (cervical or endometrial) for the various items. For all 
the items of Table 1, we did find a trend just below the 
threshold of significance (p=0.06-0.08). 
 
 
 
Conclusions: From our analysis, it emerged a good QoL for 
the whole series with similar percentages for the different 
tumour types and treatment modalities. The presence of 
tumour progression reduced QoL. We found that patients 
treated for cervical cancer complained of higher incidence of 
disuria and bladder incontinence. No patient complained of 
severe symptoms related to gastro-intestinal dysfunction or 
faecal incontinence.  
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Purpose/Objective: To correlate the vaginal toxicity to 
vaginal surface EQD23Gy dose in two protracted brachytherapy 
(BT) schedules administered after surgery for endometrial 
carcinoma. 
Materials and Methods: 319 patients (p) with EC staged after 
surgery as 2009-Figo I-IIIC underwent radiotherapy. External 
beam irradiation (EBI) plus BT was considered for high risk 
and stages II-III p and BT alone for intermediate risk p. From 
2003 to 2007 the treatment schedule for 166p was 3 
fractions(f)/week(w) of 4-6Gy after EBI (Group-1: 125p) and 
4-6Gy in 6f/2w for BT alone (Group-2: 41p). From 2007 to 
2011 the daily dose schedule in 94/153p was 2f/w of 5-6Gy 
after EBI (Group-3) and 5-6Gy in 4f in BT treatment alone 
(Group-4: 59p). The mean EBI dose in Groups 1 and 3 was 
44Gy (43-50.4). BT was performed mainly using vaginal 
cylinders. The median active length of BT treatment was 
2.5cm (2-4). Toxicity was prospectively evaluated using the 
objective criteria of LENT-SOMA. In Groups 1+3: the sum of 
EBI+BT was performed for the EQD23Gy analysis. Statistics: 
Chi-square, Fisher and Student’s-t tests. 
Results: Stage: Group-1: 29-IA, 61-IB, 12-II, 10-IIIA, 2-IIIB, 9 
IIIC1, 2-IIIC2; Group-2: 24-IA, 16-IB, 1-II; Group-3: 5-IA, 45-IB, 
14-II, 13-IIIA, 2-IIIB, 10-IIIC1, 5-IIIC2; Group-4: 33-IA, 24-IB, 
2II. Mean follow-up: Group-1: 68.08 months (m) (7.73-
123.13); Group-2 63.41m (21.2-108.56); Group-3: 47.51m 
(8.64-82.14); Group-4: 48.08m (19.23-96.66). Median overall 
BT treatment time: Group-1: 5 days (d) (3-23); Group-2: 13d 
(8-28); Group-3: 2d (2-12); Group-4: 6d (4-15). 
Vaginal cuff relapses (VCR): 5/320p, 1.56%. Group-1: 3p; 
Group-2+4: 0p; Group-3: 2p. On comparing Groups-1+3 vs. 
Groups-2+4, the incidence of VCR was 2.28% vs. 0% 
respectively (p=0.320). Late Toxicity: 1-Vagina: Group-1: 
20.8% G1-2; 0.8% G4. Group-2: 24.4%; Group-3: 26.6% G1-2; 
1.1% G4. Group-4: 20.0% G1-2. No differences were found 
between the two treatment schedules (p= 0.680) and 
between Groups-1+3 vs. Groups-2+4 (p= 0.667). The overall 
percentage of G1-G4 toxicity for Groups 1-4: 23.4%. Mean 
vaginal surface EQD23Gy: Groups 1+3: 90.02Gy, SD 13.72; 
Groups 2+4: 79.83Gy, SD 23.66; significant differences in 
EQD2 values were found between Groups 1+3 and 2+4 
(p<0.0001). Nevertheless, no correlation was found between 
the vaginal surface EQD23Gy and the development of vaginal 
complications.  
Conclusions: No differences were found in VCR and toxicity 
between the 2 BT schedules. No correlation was found 
between vaginal toxicity and vaginal surface EQD23Gy for the 
present dose per fraction schedules.  
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Purpose/Objective: From May 2010 all cervical cancer 
patients (pts) referred for brachytherapy (BT) have been MRI 
scanned. We present our retrospectively evaluated treatment 
results with gradually introduction of individualised MR-based 
plans. 
Materials and Methods: All pts referred for BT were filed in a 
separate database. Pts characteristics, morbidity and 
pathology and imaging data were obtained from the 
electronic charts. Survival data were obtained through the 
national patient registry. The radiation doses were drawn 
from Eclipse™ for the external radiation treatment (EBRT) 
and from Oncentra™ for BT. All EBRT were IMRT or rapid arc. 
BT was delivered as HDR, with a Vienna applicator, a 
Titanium Cylinder Applicator or a Steel Cylinder Applicator. 
In addition to and MRI at diagnosis, before BT and at the first 
BT fraction (F), the pts were scheduled to have a conebeam 
CT (CBCT) scan on the treatment couch at each fraction. A 
modified Embrace CRF was the basis of data collection. Data 
were processed with SPSS Predictive Analytics-software. 
Survival was calculated using the Kaplan-Meier estimate with 
a log rank test for significance. 
Results: We treated 80 pts from May 2010 to August 2014 
with the following characteristics; Median age 53.5 years [21-
83], PS0: 76.3% , PS1: 20%, PS≥2: 3.8%, stage I: 12.5%, stage 
II: 71.3%, stage ≥III: 16.3%, Histology: Squamous Cell 
Carcinoma 78.8%, Adenocarcinoma 17.5%, Small Cell 
Carcinoma 3.8%, 25% were treated as N+ disease, of these 
were 35% were bioptically verified. The EBRT PTV-T dose was 
45Gy, 50Gy or 60Gy to respectively 1.3%, 53.5% and 46.3% of 
the pts. The doses to the PTV-E were accordingly 0Gy, 45Gy 
and 49.5Gy. PTV-N was doses to 64 Gy in all cases. All but 
one pt were MRI scanned before EBRT and before BT. Planned 
BT dose was 5Gy in 5F for all pts., of those 56.3% were 
treated with a standard plan and 43.8% with a modified plan, 
from October 2012 all had modified plans. The calculated 
median dose, based on MRI before BT or MRI with applicator 
to HR-CTV90 was 104.9Gy [70.9-168.1Gy] and 96.6Gy [66.4-
146.8Gy] to HR-CTV95. The median follow up period was 29.3 
months. The pelvic control rate was 92.5%, with 3.7% failures 
inside the BT target volume. The overall survival at 4 years 
was 72.5% and significant related to Stage and nodal status, 
se figure 1. We identified 41 pts with grade 2 or more toxicity 
(tox), of these 21 pts had gastrointestinal tox, 22 had 
urological tox and 22 had vaginal tox. Some pts had tox from 
more than one organ system. 
